Psychemedics Co. (NASDAQ:PMD - Get Free Report) major shareholder Powell Anderson Capital Partne purchased 7,473 shares of Psychemedics stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $19,355.07. Following the purchase, the insider now owns 415,038 shares in the company, valued at approximately $1,074,948.42. This trade represents a 1.83 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Powell Anderson Capital Partne also recently made the following trade(s):
- On Thursday, December 12th, Powell Anderson Capital Partne purchased 75,000 shares of Psychemedics stock. The stock was acquired at an average price of $2.67 per share, with a total value of $200,250.00.
Psychemedics Trading Down 1.8 %
Shares of PMD opened at $2.67 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.01. The company's fifty day moving average is $2.37 and its two-hundred day moving average is $2.32. Psychemedics Co. has a fifty-two week low of $1.63 and a fifty-two week high of $3.93.
Psychemedics Company Profile
(
Get Free Report)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
